drug
as of 2026-07-01MP-101
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Mediti Pharma Inc.
1 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Trials
1
A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression
NCT03044249Phase 2Terminated
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
company
indication